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Review Article
Prostatic Disease and Sexual Dysfunction
Sae Woong Kim
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea
Prostatitis and benign prostatic hyperplasia (BPH) are common prostatic diseases. 
Furthermore, the incidence of prostate cancer has recently shown a rapid increase, even 
in Korea. Pain caused by prostatitis may induce sexual dysfunction, including erectile 
dysfunction and ejaculatory disturbance. And BPH itself, or treatments for BPH, may 
affect sexual function. In addition, with increased detection of localized prostate cancer, 
surgical treatments and radiation therapy have also increased, and the treatments may 
cause sexual dysfunction. Aging is also an important factor in the deterioration of the 
quality of life of men. Deterioration of quality of life caused by prostate diseases may 
be affected not only by the prostate diseases themselves but also by the sexual dysfunc-
tion caused by the prostate diseases secondarily. Thus, consideration of these points 
at the time of treatment of prostate disease is required. Therapies suitable to each con-
dition should be selected with an understanding of the close association of prostate dis-
eases and associated sexual dysfunction with the quality of life of males. 
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INTRODUCTION
Prostatitis and benign prostatic hyperplasia (BPH) are 
common prostatic diseases; the incidence of prostate can-
cer has recently shown a rapid increase, even in Korea [1]. 
Pain caused by prostatitis, which is most commonly lo-
calized to the perineum, suprapubic area, and penis, may 
induce sexual dysfunction, including erectile dysfunction 
(ED) and ejaculatory disturbance, and BPH itself, or treat-
ments for BPH, may affect sexual function. In addition, 
with increased detection of localized prostate cancer, surgi-
cal treatments and radiation therapy have also increased, 
and the treatments may cause sexual dysfunction. With ag-
ing, such prostatic diseases occur simultaneously with sex-
ual dysfunction [2-5], which is an important factor in the 
deterioration of the quality of life of men [6]. Accordingly, 
the association of prostatic diseases with sexual dysfunc-
tion was examined in the present article.
EFFECTS OF PROSTATITIS ON SEXUAL FUNCTION
Prostatitis is the most common prostatic disease in men 
younger than 50 years of age and the third most common 
urologic diagnosis in men older than 50 years of age [7]. The 
US National Institutes of Health (NIH) announced a new 
definition and classification for prostatitis, which has been 
widely accepted. Patients are divided into four categories 
by the NIH: acute bacterial prostatitis, chronic bacterial 
prostatitis, chronic prostatitis/chronic pelvic pain symp-
toms (CP/CPPS), and asymptomatic inflammatory pro-
statitis. CPPS is the most common presentation, partic-
ularly perineal, testicular, penile, and ejaculatory pain. 
Other genitourinary tract complaints include sexual dys-
function and voiding complaints [8,9]. 
　In a multicenter study from China, 1,786 patients with 
chronic prostatitis participated in a survey using the NIH 
Chronic Prostatitis Index and five questions taken from 
the International Index of Erectile Function [10]. The over-
all prevalence of sexual dysfunction in these patients was 
49%, and the prevalence of premature ejaculation and ED 
accounted for 26% and 15%. The conclusion of this study 
was that the rate of prevalence of sexual dysfunction in 
Chinese men with chronic prostatitis is high. In addition, 
age was associated with the prevalence of sexual dys-
function. 
　Considering the role of the prostate gland during ejacu-Korean J Urol 2011;52:373-378
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TABLE 1. Prevalence of sexual dysfunction and significant co-
morbidities of BPH
Study Country Prevalence Comorbidities
Braun et al [3] Germany  19% LUTS, 
hypertension, 
diabetes
Martin-Morales 
et al [16]
Spain 12-19% LUTS,  CVD, 
diabetes, heart 
disease, 
hypertension
Boyle et al [17] 4 countries  21% LUTS, 
diabetes, 
hypertension
Blanker et al 
[18]
Netherlands 3%  (50-54  yr);
26% (70-78 yr)
LUTS, obesity, 
CVD, COPD
Rosen et al [19] 7 countries 49% LUTS
LUTS: lower urinary tract symptoms, CVD: cardiovascular dis-
ease, COPD: chronic obstructive pulmonary disease 
lation, a clinical study from Italy researched the prevalence 
of chronic prostatitis in men with premature ejaculation 
[11]. Due to a higher occurrence of sexual dysfunction and 
infertility in male chronic prostatitis patients with pre-
mature ejaculation than in the control group, the study 
supposed a role for prostate inflammation in the patho-
genesis of premature ejaculation. Brown et al reported on 
the case of a 31-year-old male with prostatitis and pre-
mature ejaculation who showed improvement by cipro-
floxacin treatment [12]. A study of 145 men with premature 
ejaculation demonstrated the effectiveness of the treat-
ment in patients primarily presenting with sexual dys-
function and without symptoms of prostatitis [13]. Ninety- 
five (64.8%) of these patients had chronic bacterial prosta-
titis and 74 were given antibiotics for 1 month according 
to the results of their culture and sensitivity test. After 1 
month of antibiotic treatment, 74 patients with positive 
cultures had sterile final cultures. Sixty-two (83.9%) pa-
tients showed increases in their ejaculatory latency time 
and reported good control of their ejaculation.
　Few studies have reported on the association of CP/CPPS 
with ED. Nonetheless, CP/CPPS is believed to exert adverse 
effects on the overall quality of life, and, consequently, to 
induce ED.   
EFFECTS OF BPH ON SEXUAL FUNCTION
Lower urinary tract symptoms (LUTS) are common in ag-
ing individuals with BPH, the primary cause of LUTS in 
men over 50. The presence of histological BPH at autopsy 
is approximately 8% in men ranging in age from 31 to 40 
years, 50% in those ranging in age from 51 to 60 years, 70% 
in those ranging in age from 61 to 70 years, and 90% in those 
ranging in age from 81 to 90 years [14]. LUTS range from 
nocturia, urinary frequency, and urgency to a decreased 
and intermittent stream with incomplete bladder empty-
ing and commonly result in a decreased quality of life.
　Findings from epidemiological, pathophysiological, and 
clinical studies indicate that many of these men also suffer 
from declining sexual function, especially those under-
going treatment for their BPH-related urinary symptoms. 
Although urinary symptoms and quality of life may im-
prove with BPH therapy, the resulting effects on sexual 
function vary according to medical, surgical, and mini-
mally invasive approaches and have not been consistently 
reported.
　The incidence of both BPH and sexual dysfunction in-
creases with aging, which suggests the possibility of an as-
sociation of the two diseases. Similarly, in a study of 1216 
patients in Korea, Yong et al reported that the score for sex-
ual function decreased with severity of LUTS and aging of 
patients [2].
1. Epidemiological evidence
Data from these studies have demonstrated consistent and 
compelling evidence for an association between LUTS/ 
BPH and sexual dysfunction in aging men that is in-
dependent of the effects of age, other co-morbidities, and 
various lifestyle factors.
　Data from the National Health and Social Life Survey 
(NHSLS), a population-based representative sample of US 
adults ranging in age from 18 to 59 years, demonstrated 
a high prevalence of sexual dysfunction in men (31%) and 
women (43%) [15]. Increasing age in men was associated 
with significantly higher prevalence rates of ED. Results 
of the NHSLS also indicated that LUTS were a significant 
predictor of ED.
　A study of 2,476 Spanish men ranging in age from 25 to 
70 years indicated that the prevalence of ED was 12% to 
19%, with the rate dependent on the self-administered 
questionnaire used for assessment of sexual function [16]. 
Age-adjusted risk factors for ED included LUTS, rheu-
matic disease, circulatory disease, lung disease, diabetes, 
and hypertension.
　A population-based multinational (4 countries) study, 
the UrEpik study, investigated the relationship between 
LUTS and sexual dysfunction in 4,800 men ranging in age 
from 40 to 79 years [17]. After adjustment for age and coun-
try, men with diabetes, hypertension, or LUTS had a great-
er risk of ED.
　Some subsequent large-scale studies examining the re-
lationship between LUTS and sexual dysfunction con-
trolled not only for the effect of age but also for various medi-
cal co-morbidities and lifestyle factors (Table 1).
　In the most comprehensive study conducted to date on 
the association of age, LUTS, concomitant co-morbidities, 
and male sexual dysfunction, the MSAM-7 analyzed sur-
vey results from 12,815 men ranging in age from 50 to 80 
years in the United States and 6 European countries [19]. 
Overall, the results of this study strongly confirmed the re-
lationship between LUTS and sexual dysfunction in men, 
independent of the effects of age, other co-morbidities, and 
lifestyle factors. Sexual activity, which was reported as a 
mean of 5.9 times each month for the total sample of men, Korean J Urol 2011;52:373-378
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showed a significant decease with increasing age and the 
severity of LUTS. Sexual dysfunction also showed a sig-
nificant association with the severity of LUTS (p＜0.001). 
Logistic regression analysis, which controlled for age, med-
ical co-morbidities, tobacco use, and alcohol consumption, 
demonstrated that age and severity of LUTS were in-
dependent risk factors for sexual dysfunction. 
　The association of LUTS with sexual dysfunction in 
males after middle age has been demonstrated. However, 
to provide evidence for such results, studies characterizing 
the mechanism of the mediating effects of LUTS on sexual 
function are required.
2. Pathophysiological mechanisms
Increased smooth muscle tone in the prostate capsule and 
bladder neck can contribute to LUTS associated with BPH. 
Increased smooth muscle tone in the prostate in BPH is re-
lated to stimulation of a1-adrenergic receptors [20]. Other 
receptors that have been identified in human prostate tis-
sue and that may play a role in LUTS associated with BPH 
include dopaminergic, muscarinic, serotoninergic (5-HT2A), 
and histaminergic (H1) receptors [21]. Nitric oxide (NO), 
which is present in the human prostate [22] and modulates 
prostatic smooth muscle tone [23], may also have a role in 
the pathophysiology of LUTS associated with BPH.
　In the penis, noradrenaline and endothelins are putative 
promoters of penile detumescence (contraction), whereas 
NO promotes penile erection (relaxation). Penile erection 
involves acetylcholine-mediated relaxation of the corpus 
cavernosal smooth muscle, with neurogenic NO considered 
the main factor responsible for rapid relaxation, and endo-
thelial NO is thought to play a role in maintenance of the 
relaxed state [24,25].
1) Alpha 1-Adrenergic receptors: An imbalance in auto-
nomic control of smooth muscle contraction and relaxation 
may play an important role in both LUTS and sexual dys-
function. a1-Adrenergic receptors are known to play an im-
portant role in mediating the tone of smooth muscle cells 
in various tissues. Various a1-adrenergic receptor subtypes, 
including a1A- and a1D-receptors in prostatic stromal 
cells, urethra, and bladder, have been identified in the low-
er urinary tract [26,27]. 
　Penile detumescence and erection are dependent on the 
balance between contraction and relaxation of the corpus 
cavernosum smooth muscle [28]. In ED, the balance favors 
contraction (detumescence) rather than relaxation (erec-
tion). Noradrenaline is involved in the contraction of penile 
tissues via activation of a1-adrenergic receptors in the pen-
ile vasculature and corpus cavernosum smooth muscle, 
with androgens possibly regulating the responsiveness of 
these receptors [29].
　Adrenergic-mediated contraction of smooth muscle may 
also be regulated by Rho and Rho-associated kinase [30], 
which has been found in human prostatic smooth muscle 
cells [31] and the vas deferens of the mouse [32]. Results 
of other studies have suggested a possible role for the Rho/ 
Rho kinase pathway in the mechanism of penile smooth 
muscle contraction [33,34]. Thus, alterations in a1-adre-
nergic receptor-mediated smooth muscle tone and its regu-
lators may be a common component involved in LUTS asso-
ciated with BPH and sexual dysfunction.
2) Endothelial dysfunction: Endothelial dysfunction refers 
to impaired endothelium-dependent vasodilation result-
ing from decreased bioactivity of NO [35]. Endothelial dys-
function has been associated with aging, cardiovascular 
disease, diabetes, hypertension, and hypercholesterolemia. 
Possible mechanisms responsible for endothelial dysfunc-
tion include accelerated breakdown of NO by reactive oxy-
gen species, alterations in antioxidant defense systems, 
and alterations in the activity or expression of the endothe-
lial NO synthase (eNOS) enzyme [36]. In aging men, de-
creasing levels of testosterone and reductions in the con-
version of testosterone to estradiol by the aromatase en-
zyme may contribute to deficits in eNOS-derived NO [37].
　In prostatic tissue from men with BPH, decreased ni-
trergic innervation was demonstrated in comparison with 
that in normal prostate tissue [38], which suggests a possi-
ble role for NO in the pathophysiology of BPH. Studies in 
animals also suggest that NO plays a role in preventing the 
bladder contractions that result in bladder hyperactivity, 
as observed in LUTS [39-41].
3) Sex hormones: Dihydrotestosterone (DHT), which is 
more potent than testosterone and demonstrates a higher 
affinity for androgen receptors, is predominantly produced 
peripherally from testosterone via the enzyme 5a-reduc-
tase. Androgen receptors, which are present in both the 
stroma and the epithelium of the prostate, as well as in most 
blood vessel endothelial cells, smooth muscle cells, and fi-
brocytes [42], may play a role in the interaction between 
the stroma and epithelium of the prostate. Age-related 
changes in circulating hormone levels and an imbalance in 
the testosterone/estrogen ratio may play a role in the path-
ophysiology of BPH and sexual dysfunction.
EFFECTS OF PROSTATE CANCER ON SEXUAL 
FUNCTION
In Korea, due to the westernization of dietary habits, the 
incidence of prostate cancer has shown a gradual increase 
in the past decade. Not only the psychological stress caused 
by the prostate cancer itself but also problems such as ED 
act as factors in the deterioration of quality of life. One 
study examining the view of prostate cancer patients with 
regard to sexual function in comparison with that of males 
without prostate cancer has been reported [43]. The level 
of stress in regard to the four categories—sexual desire, 
erectile function, level of satisfaction during sexual activ-
ity, and ejaculatory volume—was examined. Psychological 
burdens in prostate cancer patients were observed to be 
higher in all categories, and 25% more prostate cancer pa-
tients reported having sexual dysfunction than patients 
without prostate cancer. Furthermore, most males consid-
ered preservation of sexual function to be of importance; 
nonetheless, a trend in selection of treatment for prostate Korean J Urol 2011;52:373-378
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cancer first was demonstrated [44]. Sexual function of pros-
tate cancer patients is affected by radical prostatectomy, 
radiation therapy, hormone therapy, and other treatment 
methods; thus, the effect of each therapy on sexual function 
is summarized in the next section. 
1. Radical prostatectomy
Erectile dysfunction after radical prostatectomy is a com-
mon complication and is caused by surgical nerve injury re-
sulting in collagenization of smooth muscles in the corpus 
cavernosum [45-47]. Twelve months after radical prosta-
tectomy, sexual function shows partial recovery, and di-
verse recovery rates have been reported, depending on 
investigators. It is influenced by the age of the patient at 
the time of surgery, presurgical sexual function of the pa-
tients, and whether nerve-preserving surgery was per-
formed. 
　The age of the patients, as well as sexual function before 
surgery, are important factors that are closely associated 
with ED. According to several reports, if the age of the pa-
tient is relatively low, the rate of recovery of erectile func-
tion after surgery is high; in particular, in localized pros-
tate cancer patients ranging in age from 40 to 49 years, re-
covery of erectile function was observed in 92% of patients 
[48-51]. In addition, patients with normal sexual function 
before surgery have an indication for nerve-preserving sur-
gery, and patients taking phosphodiesterase 5 inhibitors 
for ED before surgery show severe ED after surgery regard-
less of nerve-preserving surgery [52]. In radical prostatec-
tomy, ideal conditions for nerve-preserving surgery in-
clude localized prostate cancer with low prostate-specific 
antigen values, a low Gleason score histologically, a rela-
tively low age of the patient, and no sexual dysfunction be-
fore surgery [53]. Bilateral nerve-preserving surgery in 
such localized prostate cancer patients has been reported 
to aid in recovery of sexual function after surgery [54]. 
2. Radiotherapy
Radiation therapy, the second most common therapeutic 
method for treatment of localized prostate cancer, can re-
duce complications of surgery. It can be divided broadly in-
to external beam radiotherapy and brachytherapy [55]. 
Sexual dysfunction induced by radiation therapy is consid-
ered to be the result of vascular injury caused by radiation 
therapy [56]. According to a study reported by Sanda et al, 
patients treated with both external beam radiotherapy and 
brachytherapy showed sexual dysfunction from 2 months 
after treatment, and the probability of developing sexual 
dysfunction was high in older patients and patients simul-
taneously treated with hormone therapy [57]. 
3. Androgen deprivation therapy
Androgen deprivation therapy (ADT) is a treatment meth-
od applied to metastatic prostate cancer patients or pa-
tients detected as having biochemical recurrence after rad-
ical prostatectomy for treatment of localized prostate 
cancer. Sexual dysfunction is the most frequent complica-
tion of ADT, and it has been found that most patients under-
stood the development of sexual dysfunction to be due to 
the treatments. Nonetheless, some patients were not sat-
isfied with the deterioration of libido, ED, and other prob-
lems [58]. In addition, due the reduction of testosterone in 
the body caused by ADT, not only the size of the testis but 
also the length and volume of the penis are decreased, 
which may be recovered after termination of ADT. 
CONCLUSIONS
Prostatitis, BPH, and prostate cancer are representative 
diseases that develop in the prostate; they are closely asso-
ciated with the male, and they exert significant effects on 
quality of life. In addition, deterioration of quality of life 
caused by prostate diseases may be affected not only by the 
prostate diseases themselves but also by the sexual dys-
function caused by the prostate diseases secondarily. 
Furthermore, sexual dysfunction may develop as a side ef-
fect after treatment of prostate disease; thus, consid-
eration of these points at the time of treatment of prostate 
disease is required. Therefore, therapies suitable to each 
condition should be selected with an understanding of the 
close association of prostate diseases and associated sexual 
dysfunction with the quality of life of males. 
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